Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 5/7 cls
Elan Corp. plc (NYSE:ELN) UBS Guillaume van Renterghem Upgrade Neutral (from sell) -10% $6.02
van Renterghem upgraded after the share price fell to around his target of $7.27. He previously expected a surge in the number of reported cases of progressive multifocal leukoencephalopathy (PML) in patients receiving Tysabri natalizumab, but believes the downside risk is "now mostly priced in." Elan and Biogen Idec Inc. (NASDAQ:BIIB) market the humanized mAb against integrin alpha(4) to treat multiple sclerosis in the EU and to treat

Read the full 1096 word article

How to gain access

Continue reading with a
two-week free trial.